Last reviewed · How we verify
Pioglitazone and insulin
Pioglitazone and insulin, marketed by Takeda, is a combination therapy currently available for patients with type 2 diabetes. The key composition patent for this drug is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and financial performance.
At a glance
| Generic name | Pioglitazone and insulin |
|---|---|
| Also known as | ACTOS®, AD-4833 |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Insulin Regulation of Lipolysis and Lipolysis Proteins (EARLY_PHASE1)
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Effects of Different Early Intensive Therapies on Long-term β-cell Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone and insulin CI brief — competitive landscape report
- Pioglitazone and insulin updates RSS · CI watch RSS
- Takeda portfolio CI